These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32753127)

  • 21. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
    Arizmendez NP; Rudmik L; Poetker DM
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
    Lazaraki G; Akriviadis E; Pilpilidis I; Parisi I; Tzilves D; Tarpangos A
    Am J Gastroenterol; 2011 Dec; 106(12):2204-6. PubMed ID: 22138950
    [No Abstract]   [Full Text] [Related]  

  • 23. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies.
    Al-Samkari H
    Otolaryngol Head Neck Surg; 2019 Feb; 160(2):368. PubMed ID: 30798765
    [No Abstract]   [Full Text] [Related]  

  • 25. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation?
    Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD
    Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
    Amann A; Steiner N; Gunsilius E
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to "Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies".
    Hsu YP; Hsu CW; Chen C
    Otolaryngol Head Neck Surg; 2019 Feb; 160(2):369-370. PubMed ID: 30798740
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
    Simonds J; Miller F; Mandel J; Davidson TM
    Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab in hereditary hemorrhagic telangiectasia.
    Bose P; Holter JL; Selby GB
    N Engl J Med; 2009 May; 360(20):2143-4. PubMed ID: 19439755
    [No Abstract]   [Full Text] [Related]  

  • 30. [Rendu-Osler-Weber disease : More than just a nosebleed].
    Lücke E; Schreiber J; Zencker M; Braun-Dullaeus R; Herold J
    Internist (Berl); 2016 Jun; 57(6):610-5. PubMed ID: 27114237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
    Kanellopoulou T; Alexopoulou A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term experience with intranasal bevacizumab therapy.
    Steineger J; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.
    Lacout A; Marcy PY; El Hajjam M; Lacombe P
    Cutis; 2013 Apr; 91(4):173-4. PubMed ID: 23763075
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.
    Sehl ME; M Gruber T; McWilliams JP; Marder VJ
    Am J Hematol; 2015 Jun; 90(6):561-3. PubMed ID: 25677911
    [No Abstract]   [Full Text] [Related]  

  • 35. Bevacizumab and hereditary haemorrhagic telangiectasia.
    Cruikshank RP; Chern BW
    Med J Aust; 2011 Mar; 194(6):324-5. PubMed ID: 21426291
    [No Abstract]   [Full Text] [Related]  

  • 36. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab.
    Ho GY; Zhong E; Chern B
    Med J Aust; 2013 Nov; 199(10):658. PubMed ID: 24237088
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
    Karnezis TT; Davidson TM
    Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hereditary hemorrhagic telangiectasia/avastin.
    Davidson TM; Olitsky SE; Wei JL
    Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.